Calithera Biosciences (CALA)
(Delayed Data from OTC)
$0.02 USD
0.00 (0.00%)
Updated Sep 18, 2024 02:02 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Calithera Biosciences, Inc. [CALA]
Reports for Purchase
Showing records 1 - 20 ( 26 total )
Company: Calithera Biosciences, Inc.
Industry: Medical - Drugs
Company: Calithera Biosciences, Inc.
Industry: Medical - Drugs
Slower Enrollment Does Not Impact Our Investment Thesis; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Calithera Biosciences, Inc.
Industry: Medical - Drugs
Clinical Programs Progress Steadily; Upgrade to Buy With $8 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Calithera Biosciences, Inc.
Industry: Medical - Drugs
Oncology Studies Ready to Start; CF Program Terminated; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Calithera Biosciences, Inc.
Industry: Medical - Drugs
Start of Multiple Clinical Programs; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Calithera Biosciences, Inc.
Industry: Medical - Drugs
KEAPSAKE Interim Readout Missed; Downgrade to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Calithera Biosciences, Inc.
Industry: Medical - Drugs
Pipeline Strengthened With De-Risked Assets; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Calithera Biosciences, Inc.
Industry: Medical - Drugs
Company: Calithera Biosciences, Inc.
Industry: Medical - Drugs
Data From Telaglenastat and CB-280 Trials Expected 2H21; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Calithera Biosciences, Inc.
Industry: Medical - Drugs
Partnership Established on CD73 Program; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Calithera Biosciences, Inc.
Industry: Medical - Drugs
Clinical Study Readouts Remain on Track; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Calithera Biosciences, Inc.
Industry: Medical - Drugs
Awaiting Initial KEAPSAKE Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Calithera Biosciences, Inc.
Industry: Medical - Drugs
Opportunity Remains in Near-Term Catalysts Despite CANTATA?s Miss; Lower PT to $4; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Calithera Biosciences, Inc.
Industry: Medical - Drugs
CANTATA Topline Data Imminent; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Calithera Biosciences, Inc.
Industry: Medical - Drugs
Company: Calithera Biosciences, Inc.
Industry: Medical - Drugs
Significant Potential of Telaglenastat in Lung Cancer; Higher $9.50 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Calithera Biosciences, Inc.
Industry: Medical - Drugs
Awaiting CANTANA Topline Data in 2H20; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Calithera Biosciences, Inc.
Industry: Medical - Drugs
Advancing Telaglenastat Into NSCLC; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Calithera Biosciences, Inc.
Industry: Medical - Drugs
Targeting the Achilles? Heel of Kidney Cancer; Initiate With Buy and $7.00 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S